New molecule can prevent the invasion of blood cells by malaria parasites

NewsGuard 100/100 Score

For the first time ever, a molecule able to prevent the invasion of blood cells by parasites of the genus Plasmodium, responsible for malaria, has been identified and described by CNRS scientists, in collaboration with American and English colleagues.

Their findings, which have just been published in Nature Communications, confirm the key role that myosin A—the 'molecular motor' of Plasmodium—plays in their infiltration of human hosts and penetration of their red blood cells, which triggers malarial attacks. Myosin A is found in all forms adopted by Plasmodium during the course of an infection, which makes it a convenient target for an inhibitor.

That inhibitor is now known to exist: dubbed KNX-002, its structure and mode of binding have been determined using crystallography, and its effects tested in vitro on red blood cells. Its discovery paves the way for the development of a new class of antimalarials.

 

Source:
Journal reference:

Moussaoui, D., et al. (2023). Mechanism of small molecule inhibition of Plasmodium falciparum myosin A informs antimalarial drug design. Nature Communications. doi.org/10.1038/s41467-023-38976-7

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New malaria vaccine strain shows promise in preclinical trials